What did we learn from the World Cup Final? Drop kicking is the new headbutting. Congratulations to the Spaniards, deserved winners last night.
- Merck-Serono's oral cladribine has been approved in Russia, and will be marketed there under the name Movectro beginning some time in 2011, once reimbursement is secured.
- Biogen Idec and Swedish Orphan Biovitrum presented Phase I/II data on their long-acting Factor IX hemophilia B treatment at a conference in Argentina over the weekend.
- Does Avid have an Alzheimer's biomarker on its hands with the radioactive dye AV-45? Reuters reports.
- J&J is being sued over its children's OTC medicines recall, with plaintiffs seeking class action status. Apparently, they don't like coupons, reports Bloomberg.
- Reata has raised $78 million in a Series G (as in goodness that's a lot of money) financing led by existing investors CPMG and Novo AS. The cash will fund a second pivotal trial of the company's lead asset, bardoxolone in chronic kidney disease.